Table 3 Outcome of transplantation
Study group add-back (n = 25) | Ctrl. group deplete (CD34+ PBSC) (n = 31) | Ctrl. group replete (BM) (n = 22) | |
|---|---|---|---|
Engraftment | |||
Primary engraftment | 24 (96%) | 26 (84%) | 22 (100%) |
Secondary engraftment | 1 (4%) | 5 (16%) | − |
Total engraftment | 25 (100%) | 31 (100%) | 22 (100%) |
GvHD | |||
Acute GvHD (evaluable patients) | (n = 25) | (n = 30) | (n = 22) |
Grade 0 | 15 (60%) | 23 (77%) | 5 (23%) |
Grade I | 7 (28%) | 4 (13%) | 4 (18%) |
Grade II | 2 (8%) | 1 (3%) | 5 (23%) |
Grade III | 1 (4%) | 2 (7%) | 6 (27%) |
Grade IV | 0 (0%) | 0 (0%) | 2 (9%) |
Chronic GvHD (evaluable patients) | (n = 23) | (n = 27) | (n = 18) |
Limited | 3 (13%) | 2 (7%) | 6 (33%) |
Extended | 0 (0%) | 0 (0%) | 1 (6%) |
Survival | |||
2-year event-free survival (all) | 17 (68%) | 12 (39%) | 11 (50%) |
2-year EFS Lymphoid malignancies | 6 (50%) | 9 (56%) | 6 (46%) |
2-year EFS Myeloid malignancies | 6 (67%) | 3 (20%) | 4 (50%) |
2-year EFS MDS (RCC) | 4 (100%) | − | 1 (100%) |
Causes of death | |||
Graft failure | 0 (0%) | 0 (0%) | 0 (0%) |
GvHD | 0 (0%) | 1 (3%) | 2 (9%) |
Relapse/progressive disease | 5 (20%) | 8 (26%) | 5 (22%) |
Infection (viral) | 2 (8%) | 5 (16%) | 1 (5%) |
Infection (bacterial, fungal) | 0 (0%) | 5 (16%) | 1 (5%) |
Other | 1 (4%) | 0 (0%) | 2 (9%) |
Unrelated to transplant | 1 (4%) | 0 (0%) | 0 (0%) |
